VUMC to operate 14 Tennessee retail clinics within Walgreens
NASHVILLE, Tenn. — Walgreens and Vanderbilt University Medical Center on Wednesday announced that a subsidiary of VUMC will operate and provide all clinical services at 14 retail health clinics within Walgreens stores across middle Tennessee.
“We are pleased to announce this new collaborative relationship with Walgreens, which reflects the efforts of both our organizations to make high-quality health care services more accessible and coordinated for patients living throughout Middle Tennessee,” stated Wright Pinson, deputy CEO and chief health system officer for VUMC. “Walgreens is a widely recognized industry leader and we look forward to sharing with them our commitment to improve the health of those we serve.”
“This is a great opportunity for Walgreens to work even closer with Vanderbilt Health,” added Pat Carroll, chief medical officer for Walgreens Healthcare Clinics. “Today’s announcement demonstrates our ongoing commitment to collaborate with community health systems, like Vanderbilt Health, to offer convenient access to affordable healthcare services while helping to ensure a true continuum of care for our patients.”
The announcement builds upon the continued relationship between Walgreens and Vanderbilt Health, which has included infusion services provided throughout the middle Tennessee market and Walgreens pharmacy participation in VUMC’s clinically integrated network.
The existing clinics at these locations, currently managed by Walgreens, are planned to transition to VUMC in November, and will be an extension of the Vanderbilt Health System. The clinics will be known as Vanderbilt Health Clinic at Walgreens. Walgreens will continue to manage these clinic locations until the transition.
FDA grants full approval to Amgen’s Blincyto
SILVER SPRING, Md. — Patients with a certain type of acute lymphoblastic leukemia have a new treatment option. The Food and Drug Administration has granted Amgen’s Blincyto (blinatumomab) full approval for the treatment of Philadelphia Chromosome-positive relaped or refractory B-cell precursor ALL.
“We are pleased that the FDA has granted full approval for Blincyto, marking a significant milestone for certain patients with relapsed or refractory ALL,” Amgen EVP research and development Dr. Sean Harper said. “This approval supports the use of Blincyto in a broader spectrum of patients, including those with few options to date, such as Philadelphia chromosome-positive patients, and reinforces the potential of the [bispeciic T cell engager] platform as a novel approach to immuno-oncology.”
The drug had previously been granted breakthrough therapy designation and accelerated approval.
“Relapsed or refractory ALL is often a lethal disease, with a median overall survival of just four months on standard-of-care chemotherapy,” Moffitt Cancer Center oncologist Dr. Bijal Shah said. “As a physician, my goal is to identify treatments that improve response rates in patients with aggressive hematologic malignancies. Blincyto is an option that has been shown to help these high-risk patients fight their disease."
Astellas names 2 regional sales execs
NORTHBROOK, Ill. — Astellas has named the heads of two regional sales leads The company on Wednesday promoted David Musselman to be area VP sales, primary care and specialty care-east, and named Lynn Gerber area VP sales, primary care and specialty care-west.
“These changes will further support our efforts to ensure we’re providing valuable therapies to patients who need them,” Astellas VP sales, primary care/specialty and hospital, Steve Sabus said. “Both David and Lynn’s demonstrated ability to lead and develop high-performance teams will build on the important relationships and communication that we’ve established with our customers and accounts in key US geographies.”
Musselman’s pharmaceutical sales experience spans 20 years, most recently at Astellas as its director of regional accounts east. In that role, he led a team of regional account managers in the company’s oncology, urology, transplant and antifungal franchises. He joined the company as a Georgia regional sales manager in 2007, followed by his time as area sales director for the southeastern United States. His career began at Pfizer, where he served in various roles, including district manager. In his new role, Musselman will be based in South Carolina, overseeing a team of five sales directors and reporting to Sabus.
Musselman takes over his new role from Gerber, who has been with Astellas since 2003 and has more than 25 years of pharmaceutical industry experience. Before joining Astellas, she worked in sales, marketing and operations roles of increasing responsibility at GSK. Gerber is a member of the Healthcare Businesswomen’s Association and was the winner of its 2015 BA Luminary Award. In her new role she will be based in Illinois, overseeing a team of five sales directors.